[Bacteriological study of cefminox in the field of obstetrics and gynecology].
Cefminox (CMNX, MT-141), a new cephem antibiotic, was determined of its antibacterial activity against 304 clinical isolates with following results. CMNX was inferior to CEZ or CMZ in the activity against 78 isolates of Staphylococcus sp., but it was superior to these antibiotics in the activity against 104 isolates of E. coli. Against 53 isolates of Bacteroides sp., CMNX showed higher activity than CEZ or CMZ. In the activity against 69 isolates of Peptococcus sp. and Peptostreptococcus sp., CMNX was almost equal to CEZ.
D001439:Bacteroides / Q000187:drug effects; D002437:Cefazolin / Q000494:pharmacology; D015311:Cefmetazole; D002513:Cephamycins / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D005831:Genital Diseases, Female / Q000382:microbiology*; D006801:Humans; D010460:Peptococcus / Q000187:drug effects; D010462:Peptostreptococcus / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects
D002513:Cephamycins; D015311:Cefmetazole; D002437:Cefazolin; C046079:cefminox